67 related articles for article (PubMed ID: 9831890)
1. The 5-HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5-HT4(c) receptor.
Blondel O; Gastineau M; Langlois M; Fischmeister R
Br J Pharmacol; 1998 Oct; 125(4):595-7. PubMed ID: 9831890
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic evidence for 5-HT1A receptors associated with human retinal pigment epithelial cells in culture.
Nash MS; Osborne NN
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):510-9. PubMed ID: 9040484
[TBL] [Abstract][Full Text] [Related]
3. 5-HT4 and 5-HT2 receptors antagonistically influence gap junctional coupling between rat auricular myocytes.
Derangeon M; Bozon V; Defamie N; Peineau N; Bourmeyster N; Sarrouilhe D; Argibay JA; Hervé JC
J Mol Cell Cardiol; 2010 Jan; 48(1):220-9. PubMed ID: 19615378
[TBL] [Abstract][Full Text] [Related]
4. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.
Krobert KA; Levy FO
Br J Pharmacol; 2002 Mar; 135(6):1563-71. PubMed ID: 11906971
[TBL] [Abstract][Full Text] [Related]
5. 5-HT induces cAMP production in crypt colonocytes at a 5-HT4 receptor.
Albuquerque FC; Smith EH; Kellum JM
J Surg Res; 1998 Jul; 77(2):137-40. PubMed ID: 9733600
[TBL] [Abstract][Full Text] [Related]
6. Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes.
Castro L; Mialet-Perez J; Guillemeau A; Stillitano F; Zolk O; Eschenhagen T; Lezoualc'h F; Bochet P; Fischmeister R
J Mol Cell Cardiol; 2005 Aug; 39(2):335-44. PubMed ID: 15950987
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation.
Adham N; Zgombick JM; Bard J; Branchek TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):508-14. PubMed ID: 9808674
[TBL] [Abstract][Full Text] [Related]
8. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
Pauwels PJ; Gouble A; Wurch T
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
[TBL] [Abstract][Full Text] [Related]
9. Intestinal prokinesia by two esters of 4-amino-5-chloro-2- methoxybenzoic acid: involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo.
Crema F; Modini C; Croci T; Langlois M; de Ponti F
J Pharmacol Exp Ther; 1999 Mar; 288(3):1045-52. PubMed ID: 10027842
[TBL] [Abstract][Full Text] [Related]
10. Regulation of G protein activation and effector modulation by fusion proteins between the human 5-hydroxytryptamine(1A) receptor and the alpha subunit of G(i1): differences in receptor-constitutive activity imparted by single amino acid substitutions in G(i1)alpha.
Kellett E; Carr IC; Milligan G
Mol Pharmacol; 1999 Oct; 56(4):684-92. PubMed ID: 10496950
[TBL] [Abstract][Full Text] [Related]
11. Modulation of voltage-dependent calcium currents by serotonin in acutely isolated rat amygdala neurons.
Lin CH; Huang YC; Tsai JJ; Gean PW
Synapse; 2001 Sep; 41(4):351-9. PubMed ID: 11494406
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
Berque-Bestel I; Soulier JL; Giner M; Rivail L; Langlois M; Sicsic S
J Med Chem; 2003 Jun; 46(13):2606-20. PubMed ID: 12801225
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723.
Musser B; Mudumbi RV; Liu J; Olson RD; Vestal RE
J Pharmacol Exp Ther; 1999 Feb; 288(2):446-54. PubMed ID: 9918544
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of 5-Hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors.
Claeysen S; Sebben M; Bécamel C; Eglen RM; Clark RD; Bockaert J; Dumuis A
Mol Pharmacol; 2000 Jul; 58(1):136-44. PubMed ID: 10860935
[TBL] [Abstract][Full Text] [Related]
15. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
Moser PC; Bergis OE; Jegham S; Lochead A; Duconseille E; Terranova JP; Caille D; Berque-Bestel I; Lezoualc'h F; Fischmeister R; Dumuis A; Bockaert J; George P; Soubrié P; Scatton B
J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
[TBL] [Abstract][Full Text] [Related]
16. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus.
Blondel O; Gastineau M; Dahmoune Y; Langlois M; Fischmeister R
J Neurochem; 1998 Jun; 70(6):2252-61. PubMed ID: 9603189
[TBL] [Abstract][Full Text] [Related]
17. Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists.
Albert PR; Sajedi N; Lemonde S; Ghahremani MH
J Biol Chem; 1999 Dec; 274(50):35469-74. PubMed ID: 10585418
[TBL] [Abstract][Full Text] [Related]
18. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system.
Khawaja XZ; Smith DL; Nawoschik SP; Zhang J; Dunlop J; Dilks DW; Olsen M; Schechter LE
J Neurochem; 2006 Jul; 98(1):134-45. PubMed ID: 16805803
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide-C receptor-induced attenuation of adenylyl cyclase signaling activates phosphatidylinositol turnover in A10 vascular smooth muscle cells.
Mouawad R; Li Y; Anand-Srivastava MB
Mol Pharmacol; 2004 Apr; 65(4):917-24. PubMed ID: 15044621
[TBL] [Abstract][Full Text] [Related]
20. Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins.
Pindon A; van Hecke G; van Gompel P; Lesage AS; Leysen JE; Jurzak M
Mol Pharmacol; 2002 Jan; 61(1):85-96. PubMed ID: 11752209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
